BMS265246

A cell-permeable inhibitor of Cdk1 and Cdk2

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1650.00

1320.00

- +
10mg

￥2300.00

1840.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

BMS265246 is a potent and selective inhibitor for CDK1 and CDK2 (IC50= 6 nM and 9 nM)

Cyclin-dependent kinases (CDK) are a group of serine/threonine kinases. They are activated by coupling to cyclin and participate in the regulation of cell cycle.

BMS265246 inhibited the Cdk4/cycD activity and prevented A2780 Cytox (IC50 = 0.23 μM and 0.76 μM) [1]. In HCT-116 cells, BMS-265246 blocked the cell proliferation (EC50= 0.293 μm—0.492 μm). Following the treatment of BMS-265246, low DNA intensity, large round nuclei and 4N DNA content were observed in the dominant cell population –G2 arrested cells. [2]

参考文献:
1. Misra RN, Xiao Hy, Rawlins DB et al.? 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues.? Bioorg
Med Chem Lett.? 2003 Jul 21;13(14):2405-8.
2. Sutherland JJ, Low J, Blosser W et al.? A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54.

Protocol

Cell experiment [1]:
Cell lines	HCT-116 cells
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting condition	0.293 ~ 0.492 μM
Applications	In HCT-116 cells, BMS265246 blocked the cell proliferation with EC50 values ranging from 0.293 to 0.492 μM. Compared with R-547 group, BMS265246 group had a higher proportion of G2-apoptotic cells. BMS265246 treatment resulted in low DNA intensity, large round nuclei and 4N DNA content in the dominant cell population-G2 arrested cells.
参考文献: [1]. Sutherland JJ, Low J, Blosser W et al. A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54.